TX-EXPONENTIAL-TECH
15.12.2022 18:44:35 CET | Business Wire | Press release
Exponential Technology Group (XTG) today announced it has reached a definitive agreement to acquire Braemac Pty Ltd., a specialist in product design, development, testing, and the supply of semiconductors, systems, and electronic components. The financial terms of the deal were not disclosed.
Braemac is based in Sydney, Australia, with 17 offices globally and offers support from design through to product realization, driving innovation with industry-leading semiconductor and electronic component partners providing extensive design and supply chain management expertise.
“We welcome the Braemac team to the XTG family of companies,” said Glenn Smith, acting President of the Exponential Technology Group. “Braemac brings a very experienced management team and a business model that fits extremely well into XTG’s vision of helping engineers solve technical problems as well as having the experience and expertise to design a customer’s smart product from scratch, and then managing the bill-of-materials and supply chain through production.”
Behind these companies lies even more – the strength of XTG’s parent company, Mouser Electronics, a global authorized distributor of semiconductors and electronics components, recognized as the world leader in the introduction of new products with the widest selection of in-stock products for new designs. As a wholly-owned subsidiary of TTI Inc., Mouser and XTG are part of the Berkshire Hathaway family of companies.
According to Braemac President Jonathan Mitchell, “The Exponential Technology Group is a great fit for Braemac. Companies within XTG maintain their own areas of expertise and focus while collaborating within the group to deliver new technological solutions globally.”
Braemac was advised by Allier Capital and Norton Rose Fulbright Australia. XTG advisors in Australia were the law firm of Clayton Utz and PwC.
About Exponential Technology Group
Exponential Technology Group (XTG) is a collection of companies specializing in designing products and supplying semiconductors and electronic components that enable smart electronic systems in automotive, medical, wireless, industrial, and IoT. XTG operates as an independent member of the Mouser and TTI family of companies. The companies within the XTG group include the Design Services Companies of BGM Electronic Services, Connected Development, and Paragon Innovations, plus the supply chain experts and specialty semiconductor distributors of RFMW Ltd, Symmetry Electronics, Changnam I.N.T. LTD. To learn more, visit http://www.xponentialgroup.com/
About Braemac
Braemac is a leading distributor Headquartered in Australia, with 17 offices worldwide. Braemac supplies semiconductors, electronic components, interface products, systems, and services related to the end-product design, manufacture, and technical support for products, including single-board computers, displays, power supplies, cable assemblies, as well as value-added product assembly, and turnkey products. To learn more, visit http://www.braemac.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221215005852/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom